loader
Page is loading...
OVERVIEW

Allen R. Baum
Partner

Raleigh

4819 Emperor Boulevard
Suite 400
Durham, NC 27703

P 919-536-6207

F 919-536-6201

OVERVIEW

Allen R. Baum
Partner

Raleigh

4819 Emperor Boulevard
Suite 400
Durham, NC 27703

P 919-536-6207

F 919-536-6201

Over the course of more than 25 years as a patent attorney matched with in-house experience as a pharmaceutical chemist at DuPont Merck Pharmaceuticals and Smithkline Beecham, Allen Baum, partner-in-charge of the Raleigh office, has the ability to take complex scientific and legal issues and distill them into timely, relevant and useful counsel.

OVERVIEW

Over the course of more than 25 years as a patent attorney matched with in-house experience as a pharmaceutical chemist at DuPont Merck Pharmaceuticals and Smithkline Beecham, Allen Baum, partner-in-charge of the Raleigh office, has the ability to take complex scientific and legal issues and distill them into timely, relevant and useful counsel.

Clients hire Allen to identify and execute strategies to protect key commercial products and bring lucrative products to market in areas heavily patented by competitors. With an extensive litigation background, he is also frequently retained to evaluate the strength of patents under consideration for licensing, acquisition or investment.

Allen frequently assist clients with strategies for pursuing commercially significant patent portfolios and has managed large portfolios of patent applications for Global Fortune 100 companies. He has also provided opinions on patents protecting products with sales in excess of $1 billion. His representative clients are active in small molecule pharmaceuticals, biotechnology, biochemistry, vaccines, medical devices, ocular medications and implants, green technologies, and advanced materials. 

Allen’s work includes post grant litigation and inter partes review before the U.S. Patent and Trademark Office, freedom-to-operate studies, due diligence review, infringement and validity studies, licensing, Hatch-Waxman litigation, reexamination, and patent preparation and prosecution in the areas of chemistry, pharmaceuticals, biochemistry, biotechnology, and medical devices. 

Active in leadership roles in the IP industry, Allen is a former president of the Licensing Executives Society for the USA and Canada, a former president of the Board of Governor’s for Certified Licensing Professionals (CLP), and was managing partner of his prior firm’s Research Triangle Park office and served on its board of directors for four years. He is also a frequent instructor for intellectual asset management courses and a frequent speaker on life sciences IP topics.

Professional and Community Involvement

Instructor, Licensing Executives Society on the Fundamentals and Intermediate Intellectual Asset Management Series

Former president, Licensing Executives Society for USA and Canada

Former president and board of governors chair, Certified Licensing Professionals (CLP)

Member, American Bar Association

Member, American Intellectual Property Law Association

Member, Licensing Executives Society

Member, Triangle Intellectual Property Law Association

Honors

LMG Life Sciences Life Science Star, 2018

Managing Intellectual Property, IP Star, 2013-2018

The Best Lawyers in America, 2005-2020; Lawyer of the Year, 2018

Legal 500, Recommended Lawyer, 2017

Intellectual Asset Management, IAM Patent 1000: The World’s Leading Patent Practitioners, 2012-2018

Intellectual Asset Management, IAM 300: A Guide to the World's Leading IP Strategists, 2014

Intellectual Asset Management, IAM 250: The World’s Leading Patent & Technology Licensing Lawyers, 2010-2012

Intellectual Asset Management, IAM 250: A Guide to the World's Leading IP Strategists, 2009-2011

EXPERIENCE
Presentations
  • Freedom to Operate: Evaluating Current Strategies to Avoid Future Findings of Infringement, 17th Life Sciences Patents Summit, New York City, May 16, 2019
  • "Learning the Sweet Science: Win the New Boxing Match Known as Inter Partes Review," ACI's Comprehensive Guide to Patent Reform, New York City, Jan. 24, 2013
  • "Assessing the Impact of New PTO Procedures Under the AIA on Hatch-Waxman Strategies Relative to Patent Life Cycle Management," ACI's Maximizing Pharmaceutical Patent Life Cycles, New York City, Oct. 9, 2012
  • "Taking Action to Address Potential Roadblocks with Effective FTO Analysis" ACI’s 6th National Tactical and Practical Guide to Freedom to Operate, Philadelphia, Penn, July 31, 2012
  • "Business Implications of Patent Reform: Taking the America Invents Act Into Account in Doing Deals," Licensing Executives Society's Research Triangle Park Chapter Meeting, Durham, NC, Feb. 14, 2012
  • "Patent 101: Overview of the Fundamental Provisions in the America Invents Act" and "The Timeline of Enactment: Identifying What Needs to be Done Now and Planning for Future Changes," ACI 's Comprehensive Guide to Patent Reform for Life Science Companies, New York City, Jan. 30-31, 2012
  • "Exclusivities and Forfeitures: New Developments, Controversies and Concerns," ACI's 12th Annual Maximizing Pharmaceutical Patent Life Cycles, New York City, Oct. 5, 2011
  • "IP Law Essentials & Best Practices for Venture Capitalists: Everything You Need to Know About Protecting Intellectual Property in 60 Minutes," ExecSense Webinar, April 2011
  • "Preparing for the Exit: Drafting Critical Termination Provisions," ACI's 14th Advanced Forum on Structuring, Negotiating and Managing Life Sciences Collaborative Agreements and Acquisitions, New York, NY, Feb. 17, 2011
  • "The Role of the Regulatory Professional in the Due Diligence Process," 2010 RAPS Annual Conference & Exhibition, San Jose, CA, Oct. 25, 2010
  • "Who is on the Hook? Indemnities in Patent Sale and Licenses," Intellectual Property Owners Association Webinar, Sept. 23, 2010
INSIGHTS AND EVENTS
Trending Connect
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to use cookies.